Cargando…

Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival

Background: Natural killer (NK) cells are potential effectors in anti-cancer immunotherapy; however only a subset potently kills cancer cells. Here, we examined whether pretreatment of glioblastoma (GBM) with the proteasome inhibitor, bortezomib (BTZ), might sensitize tumour cells to NK cell lysis b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gras Navarro, Andrea, Espedal, Heidi, Joseph, Justin Vareecal, Trachsel-Moncho, Laura, Bahador, Marzieh, Tore Gjertsen, Bjørn, Klæboe Kristoffersen, Einar, Simonsen, Anne, Miletic, Hrvoje, Øyvind Enger, Per, Rahman, Mohummad Aminur, Chekenya, Martha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678126/ https://www.ncbi.nlm.nih.gov/pubmed/31319548 http://dx.doi.org/10.3390/cancers11070996

Ejemplares similares

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors–Human Leukocyte Antigen Ligand Mismatch and Activation Receptor–Ligand Interactions
por: Haspels, Heleen Neeltje, et al.
Publicado: (2018)

Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway
por: Rahman, Mohummad Aminur, et al.
Publicado: (2022)

Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
por: Blakstad, Hanne, et al.
Publicado: (2023)

Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study
por: Rahman, Mohummad A., et al.
Publicado: (2020)

Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma
por: Wang, Jian, et al.
Publicado: (2011)

Tumour-associated glial host cells display a stem-like phenotype with a distinct gene expression profile and promote growth of GBM xenografts
por: Leiss, Lina, et al.
Publicado: (2017)

The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells
por: Ryu, Sunhyo, et al.
Publicado: (2018)

Synergistic apoptosis of human gastric cancer cells by bortezomib and TRAIL
por: Bui, Hang Thi Thuy, et al.
Publicado: (2019)

A reproducible brain tumour model established from human glioblastoma biopsies
por: Wang, Jian, et al.
Publicado: (2009)

Engraftment of Human Glioblastoma Cells in Immunocompetent Rats through Acquired Immunosuppression
por: Huszthy, Peter C., et al.
Publicado: (2015)

Correction: Engraftment of Human Glioblastoma Cells in Immunocompetent Rats through Acquired Immunosuppression
por: Huszthy, Peter C., et al.
Publicado: (2015)

Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link
por: Fulda, Simone
Publicado: (2011)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
por: Lecis, D, et al.
Publicado: (2010)

Increased infiltration and tolerised antigen-specific CD8(+) T(EM) cells in tumor but not peripheral blood have no impact on survival of HCMV(+) glioblastoma patients
por: Bahador, M., et al.
Publicado: (2017)

Elevated levels of CXCL10 in the Periodic Fever, Aphthous stomatitis, Pharyngitis and cervical Adenitis syndrome (PFAPA) during and between febrile episodes; an indication of a persistent activation of the innate immune system
por: Førsvoll, Jostein, et al.
Publicado: (2013)

U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells
por: Torsvik, Anja, et al.
Publicado: (2014)

Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism
por: Bullenkamp, J, et al.
Publicado: (2014)

Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma
por: Rygh, Cecilie Brekke, et al.
Publicado: (2014)

GAK and PRKCD kinases regulate basal mitophagy
por: Munson, Michael J., et al.
Publicado: (2022)

Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells
por: Podergajs, Neža, et al.
Publicado: (2015)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
por: Gras Navarro, Andrea, et al.
Publicado: (2015)

The cholesterol transport protein GRAMD1C regulates autophagy initiation and mitochondrial bioenergetics
por: Ng, Matthew Yoke Wui, et al.
Publicado: (2022)

Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy
por: Arnesen, Victoria Smith, et al.
Publicado: (2021)

Combination of TRAIL with Bortezomib Shifted Apoptotic Signaling from DR4 to DR5 Death Receptor by Selective Internalization and Degradation of DR4
por: Bychkov, Maxim L., et al.
Publicado: (2014)

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
por: Duru, Adil Doganay, et al.
Publicado: (2015)

Gamma Knife Surgery as Monotherapy with Clinically Relevant Doses Prolongs Survival in a Human GBM Xenograft Model
por: Sandvei Skeie, Bente, et al.
Publicado: (2013)

P14.09 BORTEM-17: A Phase IB/II Single-Arm, Control Non-Randomized, Multicentre, Open Label Clinical Trial for Recurrent Glioblastoma with unmethylated MGMT promoter (NCT03643549)
por: Goplen, D, et al.
Publicado: (2021)

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
por: Trivedi, Rachana, et al.
Publicado: (2015)

Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade-4 glioma using multi-parametric MRI
por: Hannisdal, Marianne H, et al.
Publicado: (2023)

Bortezomib in Kidney Transplantation
por: Raghavan, Rajeev, et al.
Publicado: (2010)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
por: Poli, Aurélie, et al.
Publicado: (2013)

TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis
por: López-Gómez, Carlos, et al.
Publicado: (2011)

TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
por: REFAAT, ALAA, et al.
Publicado: (2014)

Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities
por: Andersen, Johannes K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qjna50ace8ld45bpo4cok725sb